Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Shionogi submits NDA for tablets to treat vulvar and vaginal atrophy

April 30, 2012

Omthera Pharmaceuticals reports topline results from EVOLVE study

April 27, 2012

Takeda receives complete response letter for alogliptin product NDAs

April 26, 2012

New insulin secretagogues designed in Japan

April 26, 2012

Pfizer patents novel acetyl-CoA carboxylase inhibitors

April 26, 2012

First medicine approved in E.U. for Cushing's disease

April 25, 2012

EMA committee maintains recommendation on Glybera

April 23, 2012

European approval of Forxiga recommended

April 23, 2012

First patient dosed in new phase I AZD-2820 trial

April 20, 2012

Depomed plans NDA filing for Serada

April 18, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...